78 related articles for article (PubMed ID: 19850448)
1. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
Steinhoff BJ; Wendling AS
Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448
[TBL] [Abstract][Full Text] [Related]
2. [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Steinhoff BJ; Stefan H; Schulze-Bonhage A; Hueber R; Paulus W; Wangemann M; Elger CE
Nervenarzt; 2012 Oct; 83(10):1292-9. PubMed ID: 22850688
[TBL] [Abstract][Full Text] [Related]
3. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
4. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
7. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid E; Kuchukhidze G; Kirschner M; Leitinger M; Höfler J; Rohracher A; Kalss G; Wendling AS; Steinhoff BJ; Trinka E
Acta Neurol Scand; 2017 Apr; 135(4):449-453. PubMed ID: 27444636
[TBL] [Abstract][Full Text] [Related]
8. [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].
Steinhoff BJ; Trinka E; Wendling AS
Nervenarzt; 2011 Jun; 82(6):764-7. PubMed ID: 21052972
[TBL] [Abstract][Full Text] [Related]
9. Oxcarbazepine extended-release formulation in epilepsy.
Steinhoff BJ
Expert Rev Clin Pharmacol; 2009 Mar; 2(2):155-62. PubMed ID: 24410646
[TBL] [Abstract][Full Text] [Related]
10. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
Ficker DM; Privitera M; Krauss G; Kanner A; Moore JL; Glauser T
Neurology; 2005 Aug; 65(4):593-5. PubMed ID: 16116122
[TBL] [Abstract][Full Text] [Related]
11. Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.
Lee SA; Heo K; Kim WJ; Song HK; Kim SE; Kim SH; No SK; Lee BI
Seizure; 2010 Jul; 19(6):356-8. PubMed ID: 20538492
[TBL] [Abstract][Full Text] [Related]
12. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
Miller AD; Krauss GL; Hamzeh FM
Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
14. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
15. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
17. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report.
Franzoni E; Garone C; Sarajlija J; Gualandi S; Malaspina E; Cecconi I; Moscano FC; Marchiani V
Seizure; 2006 Jul; 15(5):292-8. PubMed ID: 16554175
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy.
Zou XM; Chen JN; An DM; Hao NY; Hong Z; Hao XT; Rao P; Zhou D
Seizure; 2015 Jul; 29():81-5. PubMed ID: 26076847
[TBL] [Abstract][Full Text] [Related]
19. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.
Martinotti G; Di Nicola M; Romanelli R; Andreoli S; Pozzi G; Moroni N; Janiri L
Hum Psychopharmacol; 2007 Apr; 22(3):149-56. PubMed ID: 17397097
[TBL] [Abstract][Full Text] [Related]
20. [Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].
Homberg V; Kowalik A; Schulze-Bonhage A
Nervenarzt; 2001 Dec; 72(12):918-23. PubMed ID: 11789435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
